Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Fiche publication
Date publication
octobre 2018
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr LEPAGE Côme
Tous les auteurs :
Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O
Lien Pubmed
Résumé
The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2.
Mots clés
Gastric neoplasm, Prognosis, Second-line chemotherapy, Survival
Référence
Gastric Cancer. 2018 Oct 11;: